DropGenie Raises Seed+ Financing to Accelerate Commercialization of Its First Product
New funding will power foundational primary cell data generation to advance AI-driven discovery through the company’s full product launch.
MONTREAL and BOSTON, June 22, 2026 /PRNewswire/ — DropGenie, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first product. The round was led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM, and existing investors Real Ventures and Anges Québec continuing their strong support.
This funding will drive commercialization: scaling manufacturing, building commercial operations, and accelerating customer adoption. The rollout follows successful validation through DropGenie’s Early Access Program, with many major global pharma, biotech, and research customers already integrating the technology into their workflows.
DropGenie’s platform enables high-throughput, miniaturized gene editing workflows that reduce the number of cells and reagents required per experiment — lowering costs and accelerating editing turnaround time. This enables direct edits on primary patient cells, delivering more biologically relevant insights earlier in the R&D process.
